EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data

Ibon Gurruchaga Sotés iD, M Carmen Gómez-Mateo iD, María Eugenia Ortega Izquierdo, Javier Martínez-Trufero iD

Cancers · 08.01.2024 · 16 (2) · 267

DOI: 10.3390/cancers16020267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 08.01.2024. Verfasst von Ibon Gurruchaga Sotés und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of gemcitabine and dacarbazine has exhibited efficacy in terms of progression-free survival (PFS) and overall survival (OS) for aSTSs, albeit without robust confirmation from larger clinical trials.

Methods

We conducted a retrospective study in a single institution involving aSTS patients treated with gemcitabine and dacarbazine.

Results

95 patients were assessed, pointing to a benefit in PFS of 3.5 months and an OS of 14.2 months. Patients with translocated histotypes had better PFS, while those with platelet–lymphocyte ratios (PLRs) surpassing a specific threshold or lower albumin levels had poorer overall survival.

Conclusions

This study validates previous findings from three phase I–II trials, affirming the utility of this treatment approach in routine clinical practice.

Schlagwörter

Stichwörter der Autor:innen

advanced soft tissue sarcomabiomarkerdacarbazinegemcitabineprognostic index

Autor:innen und Institutionen

  • Department of Medical Oncology, Hospital Universitario de Navarra, 31008 Pamplona, Spain.
  • Instituto de Investigación Sanitaria de Aragón, 50009 Zaragoza, Spain.
  • Department of Pathology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.
  • Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain.

ORCID-Profile: Ibon Gurruchaga Sotés, M Carmen Gómez-Mateo, Javier Martínez-Trufero

Zitieren

APA

Gurruchaga Sotés, I., Gómez-Mateo, M. C., Ortega Izquierdo, M. E., & Martínez-Trufero, J. (2024). Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data. Cancers, 16(2), 267. https://doi.org/10.3390/cancers16020267

Vancouver

Gurruchaga Sotés I, Gómez-Mateo MC, Ortega Izquierdo ME, Martínez-Trufero J. Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data. Cancers. 2024;16(2):267. doi:10.3390/cancers16020267

BibTeX
@article{GurruchagaSots2024,
  author = {Gurruchaga Sotés, Ibon and Gómez-Mateo, M Carmen and Ortega Izquierdo, María Eugenia and Martínez-Trufero, Javier},
  title = {Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {267},
  doi = {10.3390/cancers16020267}
}
Kostenlos starten →